← Human Trials & Peer-Reviewed Studies
Correlations of insulin resistance and HbA1c with cytokines IGF-1, bFGF and IL-6 in the aqueous humor of patients with diabetic cataract
Plain-language guide to PMID 30657541 (2019): observational study of IGF-1 LR3 in 59 patients, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 30657541
- Journal
- European review for medical and pharmacological sciences
- Year
- 2019
- Study type
- Observational Study
- Authors
- Zhu HC et al. (3 authors)
- DOI
- 10.26355/eurrev_201901_16742
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3 in the context of insulin resistance, prediabetes & type 2 diabetes, published as an observational study.
The study aimed to investigate the correlations of insulin resistance and hemoglobin A1c (HbA1c) with cytokines [insulin-like growth factor 1 (IGF-1), basic fibroblast growth factor (bFGF) and interleukin-6 (IL-6)] in the aqueous humor of patients with diabetic cataract.
Who Took Part
The study group was 59 patients.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
59 patients with diabetic cataract and 58 patients with simple cataract treated in Jining No. 1 People´s Hospital (Jining, China) from January 2017 to February 2018, were selected randomly.
The levels of homeostasis model assessment of insulin resistance (HOMA-IR) and HbAlc, as well as IGF-1, bFGF and IL-6 in the aqueous humor were compared between the two groups.
How the Study Was Run
The correlations of HOMA-IR and HbAlc with IGF-1, bFGF and IL-6 were analyzed.
What Was Measured
Topics PubMed links to this paper include Aqueous Humor, Biomarkers, Case-Control Studies, Cataract, Diabetes Complications, Fibroblast Growth Factor 2 and Glycated Hemoglobin.
What This Means in Plain Language
This is an observational study of IGF-1 LR3 in 59 patients in people with insulin resistance, prediabetes & type 2 diabetes.
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (European review for medical and pharmacological sciences), a journal based in United States.
More context: the IGF-1 LR3 compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.